1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Mizuho Medy Co., Ltd.

Mizuho Medy Co., Ltd.

TTSE:4595
1,719.00
JPY
-1.00
(-0.06%)
31.41BMarket Cap
Nov 13Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
236.25
240.17
260.47
295.22
337.28
337.38
220.66
676.48
922.98
576.88
599.99
591.12
- -
Basic EPS, GAAP
18.75
15.15
20.74
34.65
48.25
45.9
16.08
252.86
411.47
198.12
198.07
179.8
- -
Free Cash Flow per Basic Share
10.4
-2.54
5.32
40.48
-2.44
-0.89
10.41
285.47
314.62
195.39
160.06
87.83
- -
Dividend per Share
2.5
5.72
4.62
6.25
10.5
14.5
14.49
29.97
82.45
124.94
109.93
109.04
- -
Book Value per Share
60.88
83.45
99.56
127.95
165.66
197.05
198.62
421.47
749.79
822.83
910.93
980.8
962.38
Tangible Book Value per Share
60.58
83.18
99.26
127.52
164.87
196.32
197.97
420.83
749.04
822.26
910.4
978.91
962.38
Basic Weighted Avg Shares
17
17
19
19
19
19
19
19
19
19
19
19
19
Sales/Revenue/Turnover
3,997
4,083
4,962
5,624
6,425
6,427
4,203
12,886
17,582
10,989
11,429
11,260
- -
Operating Margin (%)
18.52
16.82
10.67
15.12
19
17.29
9.9
51.98
63.16
46.92
43.07
41.32
- -
Depreciation Expense
50
52
65
77
97
166
193
173
187
195
228
266
- -
Net Income, GAAP
317
258
395
660
919
874
306
4,817
7,838
3,774
3,773
3,425
- -
Effective Tax Rate (%)
30.92
30.33
24.68
22.45
24.14
25.32
26.21
29.42
29.2
28.68
26.96
27.66
- -
Profit Margin (%)
7.94
6.31
7.96
11.74
14.31
13.6
7.29
37.38
44.58
34.34
33.01
30.42
- -
Working Capital
696
1,356
1,588
2,064
1,991
2,509
2,522
6,325
12,579
14,010
15,711
16,920
17,085
LT Debt
88
268
185
103
25
513
373
- -
- -
- -
- -
- -
- -
Total Equity
1,160
1,590
1,897
2,437
3,156
3,754
3,784
8,029
14,283
15,674
17,352
18,683
18,332
Return on Invested Capital (%)
- -
11.1
14.97
23.43
27.55
19.28
6.57
63.01
57.66
21.83
20.36
17.39
- -
Return on Capital (%)
- -
11.4
15.9
25.6
29.77
21.92
6.99
77.67
70.26
25.2
22.85
19.01
- -
Return on Common Equity (%)
- -
18.74
22.67
30.46
32.87
25.31
8.13
81.56
70.26
25.2
22.85
19.01
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
30,897
34,440
31,411

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
15,976
- -
18,171
Cash, Cash Equivalents & STI
11,150
- -
12,537
Accounts Receivable, Net
2,247
- -
2,431
Inventories
2,014
- -
2,802
Total Current Liabilities
1,782
- -
1,086
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.52%
43.64%
7.67%
Free Cash Flow
143.55%
510.11%
-45.13%
Net Income, GAAP
156.38%
294.79%
-9.22%
Sales/Revenue/Turnover
22.26%
41.61%
-1.48%
Total Cash Common Dividend
45.24%
64.12%
-0.81%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,742
1,926
- -
- -
11,429
2025
- -
- -
- -
- -
11,260
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
50.92
27.25
- -
- -
198.07
2025
- -
- -
- -
- -
179.8
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
109.93
2025
- -
- -
- -
- -
109.04
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fuminari Karakawa
Full Time Employees
193
Sector
Health technology
Industry
Medical specialties
Address
5-4 Fujinoki-machi Tosu SA Japan 841-0048
IPO Date
Dec 17, 2015
Website
mizuho-m.co.jp
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Mizuho Medy Co., Ltd. researches, develops, manufactures and sells in vitro diagnostic products and related scientific and technical information services primarily to hospitals, medical practitioners, pharmacies, drug stores and agricultural testing centers in Japan and select overseas markets including the United States, Belgium, Finland, the Netherlands, Taiwan and Thailand. Established in 1977 and headquartered in Tosu City, Saga, Japan, the company offers nucleic acid amplification test products; rapid immunoassays for in vitro diagnostic use such as SARS-CoV-2 antigen kits, influenza virus kits, RS virus kits, group A streptococcal antigen kits, adenovirus kits, Streptococcus pneumoniae antigen kits, Legionella antigen kits, norovirus antigen kits, rotavirus kits, Clostridium difficile kits, Mycoplasma pneumoniae antigen kits, Helicobacter pylori antigen kits, pregnancy test kits and ovulation test kits; densitometry analyzers; fecal occult blood test kits; biochemical liquid stable reagents; over-the-counter drugs; and fruit tree virus test drugs utilizing immune serology technology. The company distributes its products through major partners including Toho Pharmaceutical Co., Ltd., Mediceo Corporation, VITAL-NET, INC., Alfresa Corporation and SUZUKEN CO., LTD., as well as FUJIFILM Corporation and Takeda Consumer Healthcare Company Limited. In recent developments, Mizuho Medy launched the Quick Chaser SARS-CoV-2/RSV product and its product page in May 2024, and plans to exhibit at JACLaS EXPO 2024 in October 2024, underscoring ongoing expansion in rapid immunoassay offerings for infectious diseases.